In this episode of RCA Radio, host Brandon Miller sits down with Jessica Schafersman, a design and development expert at RCA®, to break down the increasingly complex world of combination products—those that blend drugs, devices, or biologics. Jessica shares insights on why these products are uniquely challenging, the regulatory expectations companies must meet, and how the FDA guidance that is intended to make the submission process streamlined. From design controls and quality system integration to the importance of human factors validation and international considerations, this episode is packed with practical advice for any company entering or expanding in the combination product space.
The compounding pharmacy industry plays a critical role in modern healthcare by offering personalized medication solutions that mass manufacturers often cannot provide. But with this important role comes a complex and evolving regulatory landscape. For compounding pharmacies, understanding the distinction between 503A and 503B facilities is essential for ensuring compliance and sustainable operation.
In this blog, we’ll break down the key differences between 503A and 503B compounders, the unique regulatory frameworks governing each, and what pharmacies need to consider if they are operating or transitioning within this space.
What Are 503A and 503B Facilities?
Under the Drug Quality and Security Act (DQSA) of 2013, compounding pharmacies are categorized into two types:
- 503A Compounding Pharmacies: These facilities prepare medications based on individual patient prescriptions. They are primarily regulated by state boards of pharmacy and must comply with the standards set forth in the United States Pharmacopeia (USP), such as USP <797> for sterile compounding.
- 503B Outsourcing Facilities: These facilities can produce larger batches of medications, often without patient-specific prescriptions, and distribute them across state lines. They are regulated by the FDA and must comply with Current Good Manufacturing Practices (CGMPs) under 21 CFR Part 211.
Key Differences Between 503A and 503B
Feature |
503A |
503B |
|
Prescription Requirement |
Required for each compounded medication |
Not required for every unit; can produce in bulk |
|
Manufacturing Standards |
USP Guidelines |
CGMP (21 CFR 211) |
|
Inspection Frequency |
= state-driven |
Risk-based FDA inspections |
|
Distribution |
Intrastate (usually) |
Interstate distribution allowed |
Why the Distinction Matters
The need for stricter oversight of compounding facilities came to the forefront following the 2012 fungal meningitis outbreak traced to the New England Compounding Center. This public health tragedy, which resulted in over 100 deaths, highlighted the dangers of unregulated mass production in pharmacy settings and prompted federal reforms that created the 503B outsourcing facility category.
Today, the 503A vs. 503B divide is more than a regulatory technicality—it’s a fundamental distinction that impacts a facility’s operations, compliance burden, and market reach.
Challenges and Considerations for Compounders
Pharmacies considering a transition from 503A to 503B status must be prepared for a significant shift in operational complexity and GMP compliance requirements. This includes:
- Building and validating cleanroom environments
- Implementing full-scale environmental and personnel monitoring programs
- Data Integrity and GDP requirements
- Complaint handling system and recalls
- Conducting process validation and product stability studies
- Cleaning validation studies
- Establishing robust quality management systems (QMS)
- Preparing for FDA inspections and potential 483 observations
Many 503B facilities also struggle with aseptic processing controls, supplier qualification programs, and adequate documentation practices—common areas cited in FDA warning letters.
Strategic Advice for Compounders
Whether you’re an established 503A pharmacy or considering expansion into 503B territory, here are key recommendations:
- Perform a Proactive Gap Assessment: Understand where your current operations fall short of 503B standards.
- Inspection Readiness
- Invest in Expertise: Consider partnering with consultants who specialize in regulatory compliance and quality systems.
- Stay Informed: Keep up with FDA guidance, warning letters, and industry trends.
- Prioritize Training and Documentation: Ensure your team is well-trained and your processes are clearly documented.
- Plan for Long-Term Compliance: Adopt a continuous improvement mindset to meet evolving expectations.
Final Thoughts
The compounding pharmacy sector is under increasing scrutiny, especially for those operating under 503B provisions. Understanding the distinctions and requirements between 503A and 503B categories is critical to maintaining compliance, avoiding regulatory pitfalls, and ultimately, delivering safe and effective medications to patients.
If you’re navigating this complex landscape, now is the time to evaluate your current state and plan strategically for the future. Compliance is no longer just about meeting minimum standards—it’s about building a foundation for long-term success. Contact RCA today to speak with our experts and get the guidance you need to stay compliant and competitive in the evolving compounding pharmacy landscape.
In this article published by Pharmaceutical Technology®, Matt Cushing, VP of Quality and Science, Nelson Labs, and Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, discuss PDA/ANSI Standard 06-2025: Assessment of Quality Culture Guidance Documents, Models, and Tools, which was published in February 2025.
Q: How can the new document from the Parenteral Drug Association (PDA), PDA/ANSI Standard 06-2025, help manufacturers and laboratories improve their culture and processes?
A: PDA/ANSI Standard 06-2025 is a consolidation of guidance documents, tools, and models to assess and improve quality culture. Companies have probably seen how the state of the quality culture can impact an organization positively or negatively. This document is a great tool to research the key aspects of culture, assess the status of your culture, and create a strategy to maintain and improve the quality culture of your organization.
Watch our FREE on-demand webinar for a deeper dive into the new Quality Standard. Click here to learn more.
Q: What is a quality culture and what does the term refer to?
A: Quality culture is something seen and felt everyday as an employee and as a consumer in our everyday lives. It is hard to put into words, but it is defined well in the PDA/ANSI 06-2025 standard as “the overriding attitude, both expressed and implied, of an organization towards quality” (1).The document breaks it down into two distinct elements: a culture of shared values, beliefs, expectations, and commitment toward quality and a structural/managerial element with defined processes that enhances quality and coordinates individual efforts. It is the cross-functional ownership of quality at all levels, as well as the beliefs and systems that drive our actions each day.
Q: What factors of a quality culture are important in the pharmaceutical industry?
A: The document has so much information on the key factors of a good quality culture. The consistent themes that stand out are:
- Leadership commitment—quality accountability, recognition, feedback loop, Gemba, visionary, strategic, enablers, respect your team, humility, trust
- Employee engagement and ownership—mission focused, striving for excellence
- Consistent standards and expectations —all sites, all teams aligned and striving for the same outcome, courage to do what is right, communicate the behaviors that you expect
- Collaboration and communication—together, sharing, learning from each other, planning
- Technical excellence—which was a newer way to group concepts that companies are familiar with, such as mature systems, competence, organizational learning, technology/innovation, and agility.
Q: Can you talk about the application of these factors in a laboratory setting and how it may differ from that of a manufacturer?
A: All of the above attributes apply and are critical for a laboratory’s quality culture, but in the authors’ opinion, some items are even more critical for a testing laboratory to succeed. In a laboratory, the main resource is people, not machines or facilities. Scientific competence and a good understanding of why things are done a certain way is paramount to producing quality results and solving problems for customers. Good leadership and employee engagement can make a huge impact on quality culture and the results achieved for clients.
Q: To what extent is the customer perspective incorporated into quality decision making?
A: The customer perspective must be embedded in strategic planning, quality systems, and day-to-day activities. The customers’ product end-users, along with their regulators, determine what good quality looks like in any particular setting. If contractors are not viewing their work through their clients’ eyes, they will miss the mark on quality. Aligning employees’ responsibilities with customers’ expectations, particularly in the pharmaceutical industry, creates employee engagement as they get excited about what customers are doing. This also creates partnerships with customers that are based on achieving mutual success. What customer doesn’t want to be understood by the provider to whom they are going for a solution?
Reference
1. PDA. PDA/ANSI Standard 06-2025: Assessment of Quality Culture Guidance Documents, Models, and Tools (PDA, February 2025).
Article details
Pharmaceutical Technology®
Vol. 49, No. 5
Page: 34